Frontlight ResearchEarly access
WithdrawnPhase 1
A Study to Evaluate ENT-01 for the Treatment of Parkinson's Disease Dementia
Key facts
- Who runs it
- Enterin Inc.
- Where
- Dayton, Fresno, and Toms River, United StatesSee the 3 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 1
- Started
- 1 Mar 2024
- Ended
- 15 Dec 2025
- Type of study
- Interventional
- Treatments tested
- Active Investigational Treatment ENT-01
- Record updated
- 1 March 2024
- Why it stopped
- Compound will not be studied for indication
Who can take part
- Age
- 30 years to 90 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 26 criteriaShow less
Who can take part
- Patients aged 30-90 years, both genders
- Patients or care-giver must provide informed consent and be willing and able to comply with study procedures
- Patients must be diagnosed with Parkinson's disease defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features: rest tremor, rigidity, bradykinesia and/or akinesia, postural and gait abnormalities
- Patients must have dementia as defined by (1) decline in cognitive function and (2) functional impairment, which together in, in the opinion of the investigator, has resulted in a clinical diagnosis of dementia
- MoCA < 24 in support of a dementia diagnosis
- Have a reliable and actively involved caregiver who must be able to communicate in English and be willing to comply with protocol requirements
- If on anti-parkinsonian agents, participants must be on stable dosage for at least 4 weeks prior to baseline
- If on medications enhancing cognition (rivastigmine, galantamine, donepezil, memantine), participants must be on stable dosage for at least 8 weeks prior to baseline
- If on antidepressant medications, participants must be on stable dosage for at least 4 weeks prior to baseline
- If on clozapine, pimavanserin or quetiapine to address drug-induced or disease-related psychosis, participants must be on stable dosage for 4 weeks prior to baseline
- Female patients of childbearing potential must have negative serum or urine pregnancy tests and must not be lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. A vasectomized partner will be allowed as one in conjunction with another single-barrier method
- Female patients unable to bear children must have this documented in the case report form (CRF) (i.e., tubal ligation, hysterectomy, or postmenopausal [defined as a minimum of one year since the last menstrual period]). Post-menopausal status will be confirmed by follicle stimulating hormone (FSH) in women less than 60 years of age
Who cannot take part
- Unable to withdraw proton pump inhibitors at the end of run-in period
- Patient or caregiver unable to administer daily oral dosing of study drug
- Caregiver unwilling or unable to unable to complete stool diary, dispense study medication and accompany the patient to all visits
- Participation in an investigational drug trial within the month prior to dosing in the present study
- A compromised gastrointestinal system which includes: Structural, metabolic, or functional GI diseases or disorders; History of major GI surgery within 30 days (a history of cholecystectomy, polypectomy, hernia repair, appendicectomy, gastric surgery for peptic ulcer and gastric banding for obesity are not exclusionary as long as they were performed more than 30 days before the screening visit. Partial or complete colectomy is exclusionary)
- Neurological disorder other than Parkinson's disease that in the opinion of the investigator might interfere with the conduct of the study
- History of excessive alcohol use or substance abuse
- Psychotic disorder was present before the diagnosis of Parkinson's disease
- Patient or caregiver unable or unwilling to provide informed consent or to comply with study procedures
- Unable to withdraw from anti-cholinergics at the beginning of the run-in period
- Any clinically significant abnormalities on screening laboratories or physical examination requiring further evaluation or treatment
- Females who are pregnant or breastfeeding
- Review of Screening period diaries indicates either of the following: Fewer than 11 days of diary completion; More than 5 complete spontaneous bowel movements per week based upon the average Complete Spontaneous Bowel Movement (CSBM) rate reported during the Screening Period
- Any other reason, which in the opinion of the investigator would confound proper interpretation of the study
Where in United States
- Elias Research - Neurology Diagnostics ResearchDayton, United States
- Neuro-Pain Medical CenterFresno, United States
- Evolution Research Group - Neuroscience Research InstitutionToms River, United States
About the trial
What the trial wants to find out
This study will be conducted as a multi-center, open label study in the US. There will be 40 patient to receive the active investigational product.
The group in the trial
- Active TreatmentTreatment being tested
ENT-01 tablet will be taken once daily by mouth.
Treatment: Active Investigational Treatment ENT-01
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter, Open Label Study to Evaluate Tolerability and Efficacy of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Dementia.
- Record updated
- 1 March 2024